Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefits only 17%–23% of patients with head and neck squamous cell carcinoma. These are cancers that arise from cells lining the mouth, throat and voice box.
❓ Unknown
Identifying Metabolic Weakness in Immune Cells Could Enhance Cancer Treatment
Just now
September 30, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
Researchers have identified a metabolic weakness in immune cells that become dysfunctional in head and neck tumors, which explains the low effectiveness of immunotherapy for head and neck squamous cell carcinoma. This discovery could lead to improved treatment options for patients suffering from this type of cancer. Understanding cancer treatment advancements is crucial for Iran, where healthcare and cancer treatment are significant public health concerns.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
12 min ago •
Deputy Minister of Interior: Creating an 'Industrial Development Layer' is the Solution for the Development…
12 min ago •
French Court Convicts Smugglers for Involuntary Homicide in Deadly Migrant Crossing
14 min ago •
Astronomers Connect Cosmic Flashes to Neutron Star Collisions
14 min ago •
Study Reveals Brain Mechanism Balancing Memory Detail and Stability
14 min ago •